HK1206297A1 - Pharmaceutical compositions for combination therapy - Google Patents
Pharmaceutical compositions for combination therapyInfo
- Publication number
- HK1206297A1 HK1206297A1 HK15106790.2A HK15106790A HK1206297A1 HK 1206297 A1 HK1206297 A1 HK 1206297A1 HK 15106790 A HK15106790 A HK 15106790A HK 1206297 A1 HK1206297 A1 HK 1206297A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- pharmaceutical compositions
- combination therapy
- therapy
- combination
- pharmaceutical
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261620203P | 2012-04-04 | 2012-04-04 | |
US201261625192P | 2012-04-17 | 2012-04-17 | |
US201361783730P | 2013-03-14 | 2013-03-14 | |
PCT/US2013/035124 WO2013152105A1 (en) | 2012-04-04 | 2013-04-03 | Pharmaceutical compositions for combination therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1206297A1 true HK1206297A1 (en) | 2016-01-08 |
Family
ID=49292803
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15106790.2A HK1206297A1 (en) | 2012-04-04 | 2015-07-16 | Pharmaceutical compositions for combination therapy |
Country Status (16)
Country | Link |
---|---|
US (3) | US20130267552A1 (xx) |
EP (1) | EP2844346B1 (xx) |
JP (1) | JP6177875B2 (xx) |
KR (1) | KR20150013476A (xx) |
CN (1) | CN104470585A (xx) |
AU (1) | AU2013243461A1 (xx) |
BR (1) | BR112014024672A8 (xx) |
CA (1) | CA2869145A1 (xx) |
EA (1) | EA027748B1 (xx) |
ES (1) | ES2776678T3 (xx) |
HK (1) | HK1206297A1 (xx) |
IL (1) | IL234831B (xx) |
MX (1) | MX2014011971A (xx) |
NZ (1) | NZ630560A (xx) |
WO (1) | WO2013152105A1 (xx) |
ZA (1) | ZA201407726B (xx) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE46117E1 (en) | 1999-12-22 | 2016-08-23 | Teva Pharmaceuticals International Gmbh | Modulators of dopamine neurotransmission |
MX2009011020A (es) * | 2007-04-12 | 2009-10-30 | Nsab Af Neurosearch Sweden Ab | Derivados de n-oxido y/o di-n-oxido de los estabilizadores/modulad ores del receptor de dopamina que exhiben perfiles mejorados de los efectos secundarios cardiovasculares. |
EP2611759A1 (en) | 2010-09-03 | 2013-07-10 | Ivax International Gmbh | Deuterated analogs of pridopidine useful as dopaminergic stabilizers |
AU2012306386B2 (en) | 2011-09-07 | 2017-06-15 | Teva Pharmaceuticals International Gmbh | Polymorphic form of pridopidine hydrochloride |
UY34503A (es) | 2011-12-08 | 2013-07-31 | Ivax Int Gmbh | ?sal de bromhidrato de pridopidina? |
US11090297B2 (en) | 2013-06-21 | 2021-08-17 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating huntington's disease |
CN105592848A (zh) | 2013-06-21 | 2016-05-18 | 梯瓦制药国际有限责任公司 | 高剂量普利多匹定用于治疗亨廷顿舞蹈症的用途 |
DK3096759T3 (da) | 2014-01-22 | 2022-05-09 | Prilenia Neurotherapeutics Ltd | Pridopidinformuleringer med modificeret frigivelse |
CA2946518C (en) * | 2014-04-25 | 2022-07-26 | Chugai Seiyaku Kabushiki Kaisha | Preparation containing tetracyclic compound at high dose |
TW201613859A (en) | 2014-06-30 | 2016-04-16 | Teva Pharma | Analogs of PRIDOPIDINE, their preparation and use |
WO2016106142A1 (en) | 2014-12-22 | 2016-06-30 | Teva Pharmaceuticals International Gmbh | L-tartrate salt of pridopidine |
US11471449B2 (en) | 2015-02-25 | 2022-10-18 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine to improve cognitive function and for treating Alzheimer's disease |
JP6887952B2 (ja) | 2015-02-25 | 2021-06-16 | プリレニア ニューロセラピューティクス リミテッド | 認知機能を改善するため、およびアルツハイマー病を治療するためのプリドピジンの使用 |
AR105434A1 (es) | 2015-07-22 | 2017-10-04 | Teva Pharmaceuticals Int Gmbh | Proceso para preparar pridopidina |
AU2017223838B2 (en) | 2016-02-24 | 2022-09-29 | Prilenia Neurotherapeutics Ltd. | Treatment of neurodegenerative eye disease using pridopidine |
EP3504187A4 (en) | 2016-08-24 | 2020-05-06 | Prilenia Neurotherapeutics Ltd. | USE OF PRIDOPIDINE FOR THE TREATMENT OF FUNCTIONAL DECLINE |
MX2019002190A (es) | 2016-08-24 | 2019-09-11 | Prilenia Therapeutics Dev Ltd | Uso de pridopidina para tratar distonías. |
DK3512506T3 (da) | 2016-09-16 | 2022-04-19 | Prilenia Neurotherapeutics Ltd | Anvendelse af pridopidin til behandling af retts syndrom |
CA3050700C (en) | 2017-01-20 | 2023-10-03 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine for the treatment of fragile x syndrome |
US11253594B2 (en) | 2017-07-07 | 2022-02-22 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Drug combinations for protecting against neuronal cell death |
US11191758B2 (en) | 2017-07-20 | 2021-12-07 | Neurolixis | Use of selective serotonin 5-HT1A receptor agonists for treating side-effects of VMAT inhibitors |
FI3668509T3 (fi) | 2017-08-14 | 2023-03-14 | Prilenia Neurotherapeutics Ltd | Menetelmä hoitaa amyotrofista lateraaliskleroosia pridopidiinilla |
CA3073568A1 (en) | 2017-08-30 | 2019-03-07 | Prilenia Neurotherapeutics Ltd. | High concentration dosage forms of pridopidine |
WO2020110128A1 (en) * | 2018-11-29 | 2020-06-04 | Prilenia Neurotherapeutics Ltd. | Combination of pridopidine and an additional therapeutic agent for treating drug induced dyskinesia |
MX2020002645A (es) | 2017-09-08 | 2021-06-10 | Prilenia Neurotherapeutics Ltd | Pridopidina para el tratamiento de las discinesias inducidas por fármacos. |
CN111615472B (zh) * | 2018-01-17 | 2023-09-01 | 赫思曼汽车通讯有限公司 | 距离接收器系统为远程的lte模块 |
JP7386544B2 (ja) * | 2018-04-25 | 2023-11-27 | シンケイ セラピューティクス インコーポレイテッド | テトラベナジン経皮送達デバイス |
Family Cites Families (81)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB850662A (en) | 1956-10-22 | 1960-10-05 | Parke Davis & Co | Substituted piperazines and processes for their production |
BE662455A (xx) | 1964-04-14 | |||
GB1060160A (en) | 1964-08-05 | 1967-03-01 | Allen & Hanburys Ltd | 4-phenylpiperidine derivatives |
US3539573A (en) | 1967-03-22 | 1970-11-10 | Jean Schmutz | 11-basic substituted dibenzodiazepines and dibenzothiazepines |
ZA7546B (en) | 1974-01-21 | 1976-08-25 | Parke Davis & Co | New antibacterial amide compounds and methods for their production |
US4048314A (en) | 1974-12-17 | 1977-09-13 | Delmar Chemicals Limited | Morpholino containing 4-arylpiperidine derivatives |
US4202898A (en) | 1978-06-05 | 1980-05-13 | Synthelabo | Method of treating anxiety and depression |
US4267328A (en) | 1978-08-01 | 1981-05-12 | Synthelabo | 1-Phenylpiperazines |
US4333942A (en) | 1979-08-03 | 1982-06-08 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Anti-depressant and analgesic 4-phenoxypiperidines |
US4518712A (en) | 1980-06-30 | 1985-05-21 | Taiho Pharmaceutical Company Limited | Piperazine derivative and analgesic composition containing the same |
GB2083476B (en) | 1980-09-12 | 1984-02-08 | Wyeth John & Brother Ltd | Heterocyclic compounds |
FR2501506A1 (fr) | 1981-03-11 | 1982-09-17 | Sanofi Sa | Compositions pharmaceutiques a action anorexigene contenant des derives de la tetrahydropyridine |
US4415736A (en) | 1981-12-28 | 1983-11-15 | E. I. Du Pont De Nemours & Co. | Certain tetrahydropyridine intermediates |
US4485109A (en) | 1982-05-07 | 1984-11-27 | E. I. Du Pont De Nemours And Company | 4-Aryl-4-piperidinecarbinols |
ATE50987T1 (de) | 1982-05-10 | 1990-03-15 | Takeda Chemical Industries Ltd | Dihydropyridinderivate, deren herstellung und verwendung. |
US4504660A (en) | 1982-07-06 | 1985-03-12 | American Home Products Corporation | Process for the production of 2,6-diaminobenzonitrile derivatives |
DE3306964A1 (de) | 1983-02-28 | 1984-09-06 | Boehringer Ingelheim KG, 6507 Ingelheim | Neues n-arylpiperazin und verfahren zu seiner herstellung |
HU198454B (en) | 1987-12-14 | 1989-10-30 | Richter Gedeon Vegyeszet | Process for production of new derivatives of tetrahydrospiridin and medical compositions containing these compounds |
FR2639226B1 (fr) | 1988-11-18 | 1993-11-05 | Sanofi | Utilisation de trifluoromethylphenyltetrahydropyridines pour la preparation de medicaments destines a combattre les troubles anxio-depressifs |
WO1991009594A1 (en) | 1989-12-28 | 1991-07-11 | Virginia Commonwealth University | Sigma receptor ligands and the use thereof |
KR100196888B1 (ko) | 1991-04-17 | 1999-06-15 | 파마시아 앤드 업죤 컴패니 | 중추 작용성을 갖는 신규한 치환된 페닐아자사이클로 알칸 |
PT100639A (pt) | 1991-06-27 | 1993-09-30 | Univ Virginia Commonwealth | Metodo para o tratamento terapeutico com compostos que sao ligandos ao receptor sigma e compostos ai utilizados, nomeadamente derivados fenilalquil-amina, aminotetralina,piperazina e piperidina |
NZ240863A (en) | 1991-09-11 | 1995-04-27 | Mcneilab Inc | Substituted 4-aryl piperidine and 4-aryl piperazine derivatives, preparation and pharmaceutical compositions thereof |
PT533268E (pt) | 1991-09-18 | 2002-02-28 | Glaxo Group Ltd | Derivados de benzanilida como antagonistas de 5-ht1d |
GB9119932D0 (en) | 1991-09-18 | 1991-10-30 | Glaxo Group Ltd | Chemical compounds |
GB9119920D0 (en) | 1991-09-18 | 1991-10-30 | Glaxo Group Ltd | Chemical compounds |
US5502050A (en) | 1993-11-29 | 1996-03-26 | Cornell Research Foundation, Inc. | Blocking utilization of tetrahydrobiopterin to block induction of nitric oxide synthesis |
IL112099A (en) | 1993-12-23 | 1999-07-14 | Ortho Pharma Corp | N-oxides of 4-arylpiperazines and 4-arylpiperidines and pharmaceutical compositions containing them |
CA2144669A1 (en) | 1994-03-29 | 1995-09-30 | Kozo Akasaka | Biphenyl derivatives |
ZA954688B (en) | 1994-06-08 | 1996-01-29 | Lundbeck & Co As H | Serotonin 5-HT1A and dopamin D2 receptor ligands |
AU6470096A (en) | 1995-07-19 | 1997-02-18 | Yoshitomi Pharmaceutical Industries, Ltd. | Fused triazole compounds |
ZA9610745B (en) | 1995-12-22 | 1997-06-24 | Warner Lambert Co | 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists |
KR100537843B1 (ko) | 1996-07-22 | 2006-04-28 | 다이이치 아스비오파마 가부시키가이샤 | 아릴피페리디놀및아릴피페리딘유도체및이들을함유하는약제 |
US5892041A (en) | 1996-08-12 | 1999-04-06 | Neurogen Corporation | Fused indolecarboxamides: dopamine receptor subtype specific ligands |
DE19637237A1 (de) | 1996-09-13 | 1998-03-19 | Merck Patent Gmbh | Piperazin-Derivate |
EP0975614A1 (en) | 1997-04-18 | 2000-02-02 | Smithkline Beecham Plc | A bicyclic aryl or a bicyclic heterocyclic ring containing compounds having a combined 5ht1a, 5ht1b and 5ht1d receptor antagonistic activity |
WO1998056787A1 (en) | 1997-06-10 | 1998-12-17 | Synthon B.V. | 4-Phenylpiperidine compounds |
SE9702716D0 (sv) | 1997-07-15 | 1997-07-15 | Ross Nicholas Waters | Substituted phenylazacycloalkanes in the treatment of cognitive disorders |
CN1182103C (zh) * | 1997-08-07 | 2004-12-29 | 株式会社富吉摩托普拉泽兹 | 乙胺衍生物 |
US6232326B1 (en) | 1998-07-14 | 2001-05-15 | Jodi A. Nelson | Treatment for schizophrenia and other dopamine system dysfunctions |
ATE253364T1 (de) | 1998-11-23 | 2003-11-15 | Sepracor Inc | Olanzapin-n-oxide enthaltende pharmaceutische zusammensetzungen |
CN1167686C (zh) | 1999-06-22 | 2004-09-22 | 神经研究公司 | 苯并咪唑衍生物和包括这些化合物的药物组合物 |
US6455543B1 (en) | 1999-07-30 | 2002-09-24 | University Of Kentucky Research Foundation | Cis-2,6-disubstituted piperidines for the treatment of psychostimulant abuse and withdrawal, eating disorders, and central nervous system diseases and pathologies |
SE9904724D0 (sv) | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission I |
SE9904723D0 (sv) | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission II |
USRE46117E1 (en) | 1999-12-22 | 2016-08-23 | Teva Pharmaceuticals International Gmbh | Modulators of dopamine neurotransmission |
AU2001280599A1 (en) | 2000-07-15 | 2002-01-30 | Smith Kline Beecham Corporation | Compounds and methods |
WO2002059117A1 (en) | 2001-01-23 | 2002-08-01 | Eli Lilly And Company | Piperazine- and piperidine-derivatives as melanocortin receptor agonists |
SE0200301D0 (sv) | 2002-02-01 | 2002-02-01 | Axon Biochemicals Bv | Thio-carbostyril derivative |
US20050004164A1 (en) | 2003-04-30 | 2005-01-06 | Caggiano Thomas J. | 2-Cyanopropanoic acid amide and ester derivatives and methods of their use |
US7160888B2 (en) | 2003-08-22 | 2007-01-09 | Warner Lambert Company Llc | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia |
ES2346452T3 (es) | 2004-06-08 | 2010-10-15 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | Nuevas fenilpiperidinas/piperazinas disustituidas utilizadas como moduladores de la neurotransmision de la dopamina. |
US7851629B2 (en) | 2004-06-08 | 2010-12-14 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | Disubstituted phenylpiperidines as modulators of dopamine and serotonin neurotransmission |
DE602005021641D1 (de) | 2004-06-08 | 2010-07-15 | Nsab, Filial Af Neurosearch Sweden Ab | Neue disubstituierte phenylpiperidine und piperazine als modulatoren der dopamin-neurotransmission |
SE0401465D0 (sv) | 2004-06-08 | 2004-06-08 | Carlsson A Research Ab | New substituted piperdines as modulators of dopamine neurotransmission |
EP1796669B1 (en) | 2004-10-01 | 2010-09-22 | Merck Sharp & Dohme Corp. | Aminopiperidines as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
WO2006040155A1 (en) | 2004-10-13 | 2006-04-20 | Neurosearch Sweden Ab | Process for the synthesis of 4-(3-methanesulfonylphenyl)-1-n-propyl-piperidine |
WO2006040156A1 (en) | 2004-10-13 | 2006-04-20 | Neurosearch Sweden Ab | Process for the synthesis of 4-(3-sulfonylphenyl)-piperidines |
AU2006283882B2 (en) | 2005-08-22 | 2011-06-23 | Solvay Pharmaceuticals B.V. | N-oxides as prodrugs of piperazine and piperidine derivatives |
SE529246C2 (sv) | 2005-10-13 | 2007-06-12 | Neurosearch Sweden Ab | Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission |
WO2007065655A1 (en) | 2005-12-07 | 2007-06-14 | Neurosearch Sweden Ab | Disubstituted phenylpiperidines as modulators of cortical catecholaminergic neurotransmission |
UA96756C2 (xx) | 2006-05-02 | 2011-12-12 | Эббот Хелскеа Продактс Б.В. | N-оксиди похідних піридилметилпіперазину та піридилметилпіперидину$n-оксиды производных пиридилметилпиперазина и пиридилметилпиперидина |
WO2007129066A1 (en) | 2006-05-05 | 2007-11-15 | Astex Therapeutics Limited | 4- (2,6-dichloro-benzoylamino) -1h-pyrazole-3-carboxylic acid (1-methanesulphonyl-piperidin-4-yl) -amide for the treatment of cancer |
EP1961742A1 (en) | 2007-02-22 | 2008-08-27 | Novartis AG | compounds of formula (I) as serine protease inhibitors |
US20100204258A1 (en) * | 2007-03-12 | 2010-08-12 | The Trustees Of Columbia University In The City Of New York | Methods and compositions for modulating insulin secretion and glucose metabolism |
MX2009011020A (es) | 2007-04-12 | 2009-10-30 | Nsab Af Neurosearch Sweden Ab | Derivados de n-oxido y/o di-n-oxido de los estabilizadores/modulad ores del receptor de dopamina que exhiben perfiles mejorados de los efectos secundarios cardiovasculares. |
TW200848063A (en) | 2007-04-23 | 2008-12-16 | Combinatorx Inc | Methods and compositions for the treatment of neurodegenerative disorders |
EP2170327B1 (en) * | 2007-06-18 | 2014-10-22 | A.Carlsson Research AB | Use of dopamine stabilizers |
GB2462611A (en) | 2008-08-12 | 2010-02-17 | Cambridge Lab | Pharmaceutical composition comprising tetrabenazine |
NZ593090A (en) | 2008-11-13 | 2013-06-28 | Link Medicine Corp | Azaquinolinone derivatives and uses thereof |
BRPI1010024A2 (pt) * | 2009-06-05 | 2019-09-24 | Link Medicine Corp | derivados de aminopirrolidinona e uso dos mesmos |
KR101401386B1 (ko) | 2009-07-29 | 2014-05-29 | 주식회사 녹십자 | 신경보호제로서의 (+)-3-하이드록시모르피난 유도체 |
JP2013501810A (ja) * | 2009-08-12 | 2013-01-17 | ヴァリーント インターナショナル(バルバドス)エスアールエル | 医薬組成物 |
US20110206782A1 (en) * | 2010-02-24 | 2011-08-25 | Auspex Pharmaceuticals, Inc. | Piperidine modulators of dopamine receptor |
WO2011107583A1 (en) * | 2010-03-04 | 2011-09-09 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders |
US20130203886A1 (en) | 2010-03-05 | 2013-08-08 | Nileshkumar Prakash Kukalyekar | Process for the production of an uhmwpe article |
US20120003330A1 (en) * | 2010-06-01 | 2012-01-05 | Auspex Pharmaceuticals, Inc. | Benzoquinolone inhibitors of vmat2 |
WO2012002863A1 (en) | 2010-07-02 | 2012-01-05 | Aktiebolaget Skf | Mechanical component and method for surface hardening |
EP2611759A1 (en) | 2010-09-03 | 2013-07-10 | Ivax International Gmbh | Deuterated analogs of pridopidine useful as dopaminergic stabilizers |
AU2012306386B2 (en) | 2011-09-07 | 2017-06-15 | Teva Pharmaceuticals International Gmbh | Polymorphic form of pridopidine hydrochloride |
UY34503A (es) | 2011-12-08 | 2013-07-31 | Ivax Int Gmbh | ?sal de bromhidrato de pridopidina? |
-
2013
- 2013-04-03 EP EP13772325.0A patent/EP2844346B1/en active Active
- 2013-04-03 CN CN201380018981.6A patent/CN104470585A/zh active Pending
- 2013-04-03 ES ES13772325T patent/ES2776678T3/es active Active
- 2013-04-03 BR BR112014024672A patent/BR112014024672A8/pt active Search and Examination
- 2013-04-03 KR KR1020147030277A patent/KR20150013476A/ko not_active Application Discontinuation
- 2013-04-03 NZ NZ630560A patent/NZ630560A/en not_active IP Right Cessation
- 2013-04-03 AU AU2013243461A patent/AU2013243461A1/en not_active Abandoned
- 2013-04-03 US US13/856,254 patent/US20130267552A1/en not_active Abandoned
- 2013-04-03 CA CA 2869145 patent/CA2869145A1/en not_active Abandoned
- 2013-04-03 WO PCT/US2013/035124 patent/WO2013152105A1/en active Application Filing
- 2013-04-03 MX MX2014011971A patent/MX2014011971A/es unknown
- 2013-04-03 JP JP2015504706A patent/JP6177875B2/ja active Active
- 2013-04-03 EA EA201491819A patent/EA027748B1/ru active IP Right Revival
-
2014
- 2014-09-23 IL IL234831A patent/IL234831B/en active IP Right Grant
- 2014-10-23 ZA ZA2014/07726A patent/ZA201407726B/en unknown
-
2015
- 2015-07-16 HK HK15106790.2A patent/HK1206297A1/xx unknown
-
2017
- 2017-06-02 US US15/612,779 patent/US20170266170A1/en not_active Abandoned
-
2018
- 2018-11-28 US US16/203,182 patent/US11207308B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
WO2013152105A1 (en) | 2013-10-10 |
US20170266170A1 (en) | 2017-09-21 |
EP2844346A1 (en) | 2015-03-11 |
BR112014024672A8 (pt) | 2018-04-03 |
ES2776678T3 (es) | 2020-07-31 |
CN104470585A (zh) | 2015-03-25 |
US20130267552A1 (en) | 2013-10-10 |
AU2013243461A1 (en) | 2014-11-06 |
EP2844346A4 (en) | 2015-11-18 |
EA201491819A1 (ru) | 2015-04-30 |
BR112014024672A2 (xx) | 2017-06-20 |
MX2014011971A (es) | 2015-01-16 |
CA2869145A1 (en) | 2013-10-10 |
NZ630560A (en) | 2016-11-25 |
EP2844346B1 (en) | 2020-01-01 |
US20200000785A1 (en) | 2020-01-02 |
JP6177875B2 (ja) | 2017-08-09 |
IL234831B (en) | 2020-10-29 |
ZA201407726B (en) | 2016-05-25 |
KR20150013476A (ko) | 2015-02-05 |
EA027748B1 (ru) | 2017-08-31 |
US11207308B2 (en) | 2021-12-28 |
JP2015515475A (ja) | 2015-05-28 |
IL234831A0 (en) | 2014-12-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1206297A1 (en) | Pharmaceutical compositions for combination therapy | |
ZA201703992B (en) | Inhalable pharmaceutical compositions | |
HK1213798A1 (zh) | 治療性化合物和組合物 | |
HK1209638A1 (en) | Pharmaceutical compositions | |
ZA201501930B (en) | Pharmaceutical composition | |
HRP20190050T1 (hr) | Farmaceutski pripravci za kombinacijsku terapiju | |
EP2832730A4 (en) | MIRABEGRAPHIC PHARMACEUTICAL COMPOSITION | |
HK1209047A1 (en) | Novel pharmaceutical composition | |
GB201420971D0 (en) | Therapeutic composition | |
IL217807A0 (en) | Therapeutic compositions | |
ZA201502987B (en) | Pharmaceutical composition | |
EP2897590A4 (en) | PHARMACEUTICAL COMPOSITION | |
GB201211153D0 (en) | Pharmaceutical compositions | |
HK1209339A1 (en) | Pharmaceutical formulations | |
EP2851078A4 (en) | PHARMACEUTICAL COMPOSITION | |
PT2814473T (pt) | Composições farmacêuticas para terapia de combinação | |
IL238075A0 (en) | pharmaceutical preparations | |
ZA201400751B (en) | Pharmaceutical composition | |
GB201219234D0 (en) | Pharmaceutical compositions | |
GB201213303D0 (en) | Pharmaceutical compositions | |
GB201204810D0 (en) | Pharmaceutical compositions | |
GB201221130D0 (en) | New pharmaceutical composition | |
GB201207628D0 (en) | New pharmaceutical composition | |
GB201207701D0 (en) | New pharmaceutical composition | |
GB201211406D0 (en) | Pharmaceutical formulations |